[
  {
    "ts": null,
    "headline": "Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro",
    "summary": "Lilly said that, in order to manage its supply and ensure that patients maintain access, it has allocations in place for pharmacies and providers that order medicines from the company.  The drugmaker is set to increase the UK list price of the drug by up to 170% in September amid a White House push to get drugmakers to raise medicine prices in Europe to allow for price cuts in the United States.  The price for a month's supply of the highest dose of the medicine will increase from 122 pounds to 330 pounds ($164.81 to $445.80).",
    "url": "https://finnhub.io/api/news?id=3f67870e092265493356eddd603d0d9c1ae7e0825988f91b34945276bae42b11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756334275,
      "headline": "Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro",
      "id": 136557750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly said that, in order to manage its supply and ensure that patients maintain access, it has allocations in place for pharmacies and providers that order medicines from the company.  The drugmaker is set to increase the UK list price of the drug by up to 170% in September amid a White House push to get drugmakers to raise medicine prices in Europe to allow for price cuts in the United States.  The price for a month's supply of the highest dose of the medicine will increase from 122 pounds to 330 pounds ($164.81 to $445.80).",
      "url": "https://finnhub.io/api/news?id=3f67870e092265493356eddd603d0d9c1ae7e0825988f91b34945276bae42b11"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy",
    "summary": "On August 27, 2025, Eli Lilly and Company announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a statistically significant and clinically meaningful improvement in OS compared to ET alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.",
    "url": "https://finnhub.io/api/news?id=0b61c741a46e579da2fb53840201d23c5a022ad54088153b4225095e43eb2f24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756328580,
      "headline": "Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy",
      "id": 136557751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On August 27, 2025, Eli Lilly and Company announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a statistically significant and clinically meaningful improvement in OS compared to ET alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.",
      "url": "https://finnhub.io/api/news?id=0b61c741a46e579da2fb53840201d23c5a022ad54088153b4225095e43eb2f24"
    }
  },
  {
    "ts": null,
    "headline": "NVIDIA Announces Financial Results for Second Quarter Fiscal 2026",
    "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Revenue of $46.7 billion, up 6% from Q1 and up 56% from a year agoData Center revenue of $41.1 billion, up 5% from Q1 and up 56% from a year agoBlackwell Data Center revenue grew 17% sequentially SANTA CLARA, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported revenue for the second quarter ended July 27, 2025, of $46.7 billion, up 6% from the previous quarter and up 56% from a year ago. NVID",
    "url": "https://finnhub.io/api/news?id=47c1cc54f9807b2f3c76e77f0556452d6a06aa3c4d6e806f5aeb97db5150f9f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756326000,
      "headline": "NVIDIA Announces Financial Results for Second Quarter Fiscal 2026",
      "id": 136541154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Revenue of $46.7 billion, up 6% from Q1 and up 56% from a year agoData Center revenue of $41.1 billion, up 5% from Q1 and up 56% from a year agoBlackwell Data Center revenue grew 17% sequentially SANTA CLARA, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported revenue for the second quarter ended July 27, 2025, of $46.7 billion, up 6% from the previous quarter and up 56% from a year ago. NVID",
      "url": "https://finnhub.io/api/news?id=47c1cc54f9807b2f3c76e77f0556452d6a06aa3c4d6e806f5aeb97db5150f9f2"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
    "summary": "Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal",
    "url": "https://finnhub.io/api/news?id=5cd95580d17289856d993b9c007e4d390a9e1b2274662960bb75090d5b9887fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756317546,
      "headline": "Sector Update: Health Care Stocks Advance Wednesday Afternoon",
      "id": 136541206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal",
      "url": "https://finnhub.io/api/news?id=5cd95580d17289856d993b9c007e4d390a9e1b2274662960bb75090d5b9887fe"
    }
  },
  {
    "ts": null,
    "headline": "Drugmaker pauses UK sales of weight-loss jab Mounjaro",
    "summary": "One of the world’s biggest drugmakers has halted the sale of weight-loss jabs to the UK as patients race to beat a looming 170pc price rise.",
    "url": "https://finnhub.io/api/news?id=8c5ef77f66048753f2f85c57b4e6cfeb86741b396c81a8c3a1c47c7151990ccc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756316510,
      "headline": "Drugmaker pauses UK sales of weight-loss jab Mounjaro",
      "id": 136539539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One of the world’s biggest drugmakers has halted the sale of weight-loss jabs to the UK as patients race to beat a looming 170pc price rise.",
      "url": "https://finnhub.io/api/news?id=8c5ef77f66048753f2f85c57b4e6cfeb86741b396c81a8c3a1c47c7151990ccc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Highlights Positive Trial Results For Verzenio And Orforglipron",
    "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE and ATTAIN-2 trials, signaling significant advancements in their cancer and obesity treatments. The stock rose 5% over the past week, reflecting investor enthusiasm toward these medical advancements. This gain aligns with the broader market movement, which saw the market rise 1% over the same period, buoyed by anticipation surrounding Nvidia's earnings. While the overall market benefitted from tech sector optimism, Eli...",
    "url": "https://finnhub.io/api/news?id=53bf11c99885c8aa02e595148d2ab772e5228e8e466cdad9e6660d3ac92458b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756315782,
      "headline": "Eli Lilly (LLY) Highlights Positive Trial Results For Verzenio And Orforglipron",
      "id": 136539394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE and ATTAIN-2 trials, signaling significant advancements in their cancer and obesity treatments. The stock rose 5% over the past week, reflecting investor enthusiasm toward these medical advancements. This gain aligns with the broader market movement, which saw the market rise 1% over the same period, buoyed by anticipation surrounding Nvidia's earnings. While the overall market benefitted from tech sector optimism, Eli...",
      "url": "https://finnhub.io/api/news?id=53bf11c99885c8aa02e595148d2ab772e5228e8e466cdad9e6660d3ac92458b5"
    }
  },
  {
    "ts": null,
    "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
    "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
    "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756307820,
      "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
      "id": 136539545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
      "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?",
    "summary": "NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.",
    "url": "https://finnhub.io/api/news?id=056e5e77591a5be9dd2fa18ee285a789f3f5fbf3dcd674b5f686167bbb511849",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756306320,
      "headline": "Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?",
      "id": 136538825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.",
      "url": "https://finnhub.io/api/news?id=056e5e77591a5be9dd2fa18ee285a789f3f5fbf3dcd674b5f686167bbb511849"
    }
  },
  {
    "ts": null,
    "headline": "2024 saw growth recovery for almost all top biopharma companies",
    "summary": "Eli Lilly experienced the highest revenue growth of 32% to $45bn, followed by Novo Nordisk with 25.5% growth to $42.1bn.",
    "url": "https://finnhub.io/api/news?id=099e4c7ce332464d37efcf30b240ce943fe3395990db5a5daa5b22bfd7f4d924",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756305129,
      "headline": "2024 saw growth recovery for almost all top biopharma companies",
      "id": 136538826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly experienced the highest revenue growth of 32% to $45bn, followed by Novo Nordisk with 25.5% growth to $42.1bn.",
      "url": "https://finnhub.io/api/news?id=099e4c7ce332464d37efcf30b240ce943fe3395990db5a5daa5b22bfd7f4d924"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on Arya’s Substack by Arya. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $695.33 as of August 25th. LLY’s trailing and forward P/E were 45.45 and 30.49 respectively according to Yahoo Finance. Eli Lilly & […]",
    "url": "https://finnhub.io/api/news?id=63b8cb1c1035bc8bcac368d07563833415f8652b635b0c825628144ece01304d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303366,
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "id": 136539552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Eli Lilly and Company on Arya’s Substack by Arya. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $695.33 as of August 25th. LLY’s trailing and forward P/E were 45.45 and 30.49 respectively according to Yahoo Finance. Eli Lilly & […]",
      "url": "https://finnhub.io/api/news?id=63b8cb1c1035bc8bcac368d07563833415f8652b635b0c825628144ece01304d"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)",
    "summary": "Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock.",
    "url": "https://finnhub.io/api/news?id=31dfecfad5b4bb6efefab8adbee025974514cff69b62c0d4cd4d7542333ffb68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303200,
      "headline": "Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)",
      "id": 136538048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock.",
      "url": "https://finnhub.io/api/news?id=31dfecfad5b4bb6efefab8adbee025974514cff69b62c0d4cd4d7542333ffb68"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Aug 27, 2025",
    "summary": "Companies in The News Are: BNS,SMTC,LLY,SATS,T",
    "url": "https://finnhub.io/api/news?id=413184b7b187f1a32a3af59e3e9021a48643f39fdbd67ca064930a5edc00422a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756301700,
      "headline": "Company News for Aug 27, 2025",
      "id": 136537636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies in The News Are: BNS,SMTC,LLY,SATS,T",
      "url": "https://finnhub.io/api/news?id=413184b7b187f1a32a3af59e3e9021a48643f39fdbd67ca064930a5edc00422a"
    }
  },
  {
    "ts": null,
    "headline": "Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls",
    "summary": "Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=cb53ef7b31dad838eac1d7bafdc82cfd746b0c52d35a7ea73b3ffbae43ef703f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756301658,
      "headline": "Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls",
      "id": 136537089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=cb53ef7b31dad838eac1d7bafdc82cfd746b0c52d35a7ea73b3ffbae43ef703f"
    }
  },
  {
    "ts": null,
    "headline": "Update: HSBC Upgrades Eli Lilly to Hold From Reduce, Adjusts Price Target to $700 From $675",
    "summary": "(Updated to include HSBC's commentary) HSBC upgraded Eli Lilly (LLY) to hold from reduce, noting",
    "url": "https://finnhub.io/api/news?id=3e0774224312a9a361ee29e3bd1a458af85626f254794083b5d679f7f4b79404",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756301614,
      "headline": "Update: HSBC Upgrades Eli Lilly to Hold From Reduce, Adjusts Price Target to $700 From $675",
      "id": 136536294,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updated to include HSBC's commentary) HSBC upgraded Eli Lilly (LLY) to hold from reduce, noting",
      "url": "https://finnhub.io/api/news?id=3e0774224312a9a361ee29e3bd1a458af85626f254794083b5d679f7f4b79404"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday",
    "summary": "Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV)",
    "url": "https://finnhub.io/api/news?id=bb8326fc5a97d5983e51cefcbc58e419e06f7b5b12056db38d785a60a8818a91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756300245,
      "headline": "Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday",
      "id": 136536295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV)",
      "url": "https://finnhub.io/api/news?id=bb8326fc5a97d5983e51cefcbc58e419e06f7b5b12056db38d785a60a8818a91"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Nvidia Earnings Report",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad",
    "url": "https://finnhub.io/api/news?id=925dcbe439b4f56e65eb5ff0ed0331d7e16ff1790f01e8a64abbba0f2fe3a960",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756299017,
      "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Nvidia Earnings Report",
      "id": 136536296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad",
      "url": "https://finnhub.io/api/news?id=925dcbe439b4f56e65eb5ff0ed0331d7e16ff1790f01e8a64abbba0f2fe3a960"
    }
  },
  {
    "ts": null,
    "headline": "HSBC upgrades Eli Lilly to Hold, says ’bear case has played out’",
    "summary": "Investing.com -- HSBC upgraded Eli Lilly to Hold from Reduce, saying its bear case has now run its course and the risk-reward profile looks more balanced.",
    "url": "https://finnhub.io/api/news?id=c5071643350eff7a6ce902141182cddaad291112035288e5a3303f03d859aa37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756298690,
      "headline": "HSBC upgrades Eli Lilly to Hold, says ’bear case has played out’",
      "id": 136536297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC upgraded Eli Lilly to Hold from Reduce, saying its bear case has now run its course and the risk-reward profile looks more balanced.",
      "url": "https://finnhub.io/api/news?id=c5071643350eff7a6ce902141182cddaad291112035288e5a3303f03d859aa37"
    }
  },
  {
    "ts": null,
    "headline": "Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?",
    "summary": "LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.",
    "url": "https://finnhub.io/api/news?id=1d1734b0531ad1aa234686177478cd0ffa11c96e7814c31124704da79d14dafc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756296660,
      "headline": "Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?",
      "id": 136536298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.",
      "url": "https://finnhub.io/api/news?id=1d1734b0531ad1aa234686177478cd0ffa11c96e7814c31124704da79d14dafc"
    }
  },
  {
    "ts": null,
    "headline": "LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?",
    "summary": "Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.",
    "url": "https://finnhub.io/api/news?id=0d7fb7dee8f54f0b6063611503ff4a77f6f85988f104bf3aa171a69729c5e295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756296480,
      "headline": "LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?",
      "id": 136536299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.",
      "url": "https://finnhub.io/api/news?id=0d7fb7dee8f54f0b6063611503ff4a77f6f85988f104bf3aa171a69729c5e295"
    }
  },
  {
    "ts": null,
    "headline": "Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize",
    "summary": "The global binge eating disorders (BED) market is growing due to new diagnostic advances and tailored treatments improving patient care. BED, marked by episodes of excessive eating and distress, benefits from advancements in digital health, AI diagnostics, and teletherapy, enhancing early detection and access to care. Anticonvulsant medications, notably Topiramate, lead the market due to proven efficacy. North America dominates the sector, driven by mental health initiatives and robust healthcar",
    "url": "https://finnhub.io/api/news?id=7717c84c28786b5f48220415e38d695d53f29ea18b7b2553c3e4f9581f6a503b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756296000,
      "headline": "Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize",
      "id": 136536300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The global binge eating disorders (BED) market is growing due to new diagnostic advances and tailored treatments improving patient care. BED, marked by episodes of excessive eating and distress, benefits from advancements in digital health, AI diagnostics, and teletherapy, enhancing early detection and access to care. Anticonvulsant medications, notably Topiramate, lead the market due to proven efficacy. North America dominates the sector, driven by mental health initiatives and robust healthcar",
      "url": "https://finnhub.io/api/news?id=7717c84c28786b5f48220415e38d695d53f29ea18b7b2553c3e4f9581f6a503b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly eyes orforglipron approval after Phase III diabetes trial success",
    "summary": "The highest dose of the oral GLP-1RA drug reduced body weight by an average of 10.5%.",
    "url": "https://finnhub.io/api/news?id=da29f9c4c548b4bc6499de034b0460b806d81bca5f86f845b7d5bddf31fc068e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756294777,
      "headline": "Eli Lilly eyes orforglipron approval after Phase III diabetes trial success",
      "id": 136536301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The highest dose of the oral GLP-1RA drug reduced body weight by an average of 10.5%.",
      "url": "https://finnhub.io/api/news?id=da29f9c4c548b4bc6499de034b0460b806d81bca5f86f845b7d5bddf31fc068e"
    }
  },
  {
    "ts": null,
    "headline": "Positive ATTAIN-2 Results for Oral GLP-1 Could Be a Game Changer For Eli Lilly (LLY)",
    "summary": "On August 26, 2025, Eli Lilly announced positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes, with all three doses achieving significant weight loss and key secondary endpoints over 72 weeks. This milestone provides Lilly with the comprehensive clinical data needed to begin global regulatory submissions, positioning orforglipron as a potential convenient oral...",
    "url": "https://finnhub.io/api/news?id=7f9b1fb83089c6b67e3fe590c6fb776997a482e94abc0b8950398c9f154a180b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756290011,
      "headline": "Positive ATTAIN-2 Results for Oral GLP-1 Could Be a Game Changer For Eli Lilly (LLY)",
      "id": 136536303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On August 26, 2025, Eli Lilly announced positive topline results from its Phase 3 ATTAIN-2 trial of orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes, with all three doses achieving significant weight loss and key secondary endpoints over 72 weeks. This milestone provides Lilly with the comprehensive clinical data needed to begin global regulatory submissions, positioning orforglipron as a potential convenient oral...",
      "url": "https://finnhub.io/api/news?id=7f9b1fb83089c6b67e3fe590c6fb776997a482e94abc0b8950398c9f154a180b"
    }
  },
  {
    "ts": null,
    "headline": "Nasdaq Futures Tread Water With Nvidia Earnings in Focus",
    "summary": "September Nasdaq 100 E-Mini futures (NQU25) are trending up +0.02% this morning, with investors in wait-and-see mode ahead of a highly anticipated earnings report from AI darling Nvidia.",
    "url": "https://finnhub.io/api/news?id=09f00a36e470d08adcb4e87f1e6229db824094523d0d582b27f08df07fdaba59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756289075,
      "headline": "Nasdaq Futures Tread Water With Nvidia Earnings in Focus",
      "id": 136536574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "September Nasdaq 100 E-Mini futures (NQU25) are trending up +0.02% this morning, with investors in wait-and-see mode ahead of a highly anticipated earnings report from AI darling Nvidia.",
      "url": "https://finnhub.io/api/news?id=09f00a36e470d08adcb4e87f1e6229db824094523d0d582b27f08df07fdaba59"
    }
  },
  {
    "ts": null,
    "headline": "Redwire Corporation (RDW): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Redwire Corporation on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on RDW. Redwire Corporation’s share was trading at $8.70 as of August 20th. Redwire is emerging as a critical player in the space economy, evolving from a niche space infrastructure provider into a multidisciplinary aerospace and […]",
    "url": "https://finnhub.io/api/news?id=473b80ecc513e84ec3c0153c0ae4d203317b2e50b300d6dc691e0d4b6e7fa27b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285734,
      "headline": "Redwire Corporation (RDW): A Bull Case Theory",
      "id": 136536304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Redwire Corporation on topsecretstocks’s Substack. In this article, we will summarize the bulls’ thesis on RDW. Redwire Corporation’s share was trading at $8.70 as of August 20th. Redwire is emerging as a critical player in the space economy, evolving from a niche space infrastructure provider into a multidisciplinary aerospace and […]",
      "url": "https://finnhub.io/api/news?id=473b80ecc513e84ec3c0153c0ae4d203317b2e50b300d6dc691e0d4b6e7fa27b"
    }
  },
  {
    "ts": null,
    "headline": "The bear case on Eli Lilly has played out, says only firm to have called it a sell",
    "summary": "The bear case on Eli Lilly has played out, says only firm to have called it a sell",
    "url": "https://finnhub.io/api/news?id=4b191c1402b3c60701912ff7eae83b5fdb8762f193db15fccaf5d41898acc244",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756279500,
      "headline": "The bear case on Eli Lilly has played out, says only firm to have called it a sell",
      "id": 136541725,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "The bear case on Eli Lilly has played out, says only firm to have called it a sell",
      "url": "https://finnhub.io/api/news?id=4b191c1402b3c60701912ff7eae83b5fdb8762f193db15fccaf5d41898acc244"
    }
  },
  {
    "ts": null,
    "headline": "A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant",
    "summary": "Newcomers looking for a way into the obesity space are developing unique methods to snag market share.",
    "url": "https://finnhub.io/api/news?id=88e39e0304f9f453394eea2b3163954581c270c52910ab1874e6a6025750e9ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756279155,
      "headline": "A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant",
      "id": 136536305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Newcomers looking for a way into the obesity space are developing unique methods to snag market share.",
      "url": "https://finnhub.io/api/news?id=88e39e0304f9f453394eea2b3163954581c270c52910ab1874e6a6025750e9ff"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Remains Positive as Eli Lilly (LLY) Expands Obesity Drug Pipeline",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top stocks to buy and hold forever. The company’s strength lies in its strong moat from a patent-protected drug pipeline and diabetes/obesity leadership. Eli Lilly and Company (NYSE:LLY) estimates its addressable market of patients with obesity and obesity-related co-morbidities to be over 170 million patients in the US, […]",
    "url": "https://finnhub.io/api/news?id=cd909675ae970fe4bbb573328316c23e4a6f0ad727da182fe3a521ff790057f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756266832,
      "headline": "Goldman Sachs Remains Positive as Eli Lilly (LLY) Expands Obesity Drug Pipeline",
      "id": 136536306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top stocks to buy and hold forever. The company’s strength lies in its strong moat from a patent-protected drug pipeline and diabetes/obesity leadership. Eli Lilly and Company (NYSE:LLY) estimates its addressable market of patients with obesity and obesity-related co-morbidities to be over 170 million patients in the US, […]",
      "url": "https://finnhub.io/api/news?id=cd909675ae970fe4bbb573328316c23e4a6f0ad727da182fe3a521ff790057f7"
    }
  }
]